Payment overview · 2025
General Payments
$92.83
5 reported records · 4 companies
Healthcare provider profile · identity verified
Keisha Ellis, NP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner · ORLANDO, FL · NPI 1508318494
Verified facts
What the public records show
CMS Open Payments records show Keisha Ellis, NP received $92.83 in general payments during 2025 across 5 reported records.
ABBVIE INC. accounted for 33.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 5 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Ubrelvy by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Vraylar by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $31.05 | 33.5% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $24.17 | 26.0% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $19.27 | 20.8% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $18.34 | 19.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $92.83 | 5 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $31.05 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $24.17 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $19.27 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $18.34 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $18.34 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 62 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
62 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 395 | 136 |
| Levothyroxine Sodium | Levothyroxine Sodium | 254 | 75 |
| Lisinopril | Lisinopril | 213 | 72 |
| Potassium Chloride | Potassium Chloride | 207 | 80 |
| Gabapentin | Gabapentin | 204 | 66 |
| Omeprazole | Omeprazole | 190 | 52 |
| Montelukast Sodium | Montelukast Sodium | 184 | 66 |
| Amlodipine Besylate | Amlodipine Besylate | 174 | 60 |
| Metformin Hcl | Metformin Hcl | 155 | 56 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 134 | 46 |
| Pantoprazole Sodium | Pantoprazole Sodium | 118 | 34 |
| Trazodone Hcl | Trazodone Hcl | 115 | 31 |
| Azelastine Hcl | Azelastine Hcl | 113 | 56 |
| Losartan Potassium | Losartan Potassium | 111 | 35 |
| Furosemide | Furosemide | 102 | 35 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 102 | 19 |
| Metoprolol Succinate | Metoprolol Succinate | 94 | 32 |
| Farxiga | Dapagliflozin Propanediol | 93 | 20 |
| Tamsulosin Hcl | Tamsulosin Hcl | 92 | 27 |
| Ezetimibe | Ezetimibe | 86 | 31 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 85 | 23 |
| Carvedilol | Carvedilol | 80 | 20 |
| Ibuprofen | Ibuprofen | 77 | 29 |
| Sertraline Hcl | Sertraline Hcl | 74 | 24 |
| Fluticasone Propionate | Fluticasone Propionate | 65 | 35 |
| Hydrochlorothiazide | Hydrochlorothiazide | 64 | 21 |
| Ozempic | Semaglutide | 62 | 12 |
| Glipizide | Glipizide | 61 | 20 |
| Diclofenac Sodium | Diclofenac Sodium | 59 | 17 |
| Ibandronate Sodium | Ibandronate Sodium | 59 | 19 |
| Lorazepam | Lorazepam | 57 | suppressed |
| Simvastatin | Simvastatin | 54 | 20 |
| Trulicity | Dulaglutide | 52 | 13 |
| Glipizide Er | Glipizide | 51 | 16 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 51 | 17 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 49 | 16 |
| Famotidine | Famotidine | 49 | 17 |
| Jardiance | Empagliflozin | 49 | 14 |
| Clopidogrel | Clopidogrel Bisulfate | 46 | 11 |
| Azithromycin | Azithromycin | 45 | 30 |
| Spironolactone | Spironolactone | 44 | 17 |
| Buspirone Hcl | Buspirone Hcl | 41 | 11 |
| Ventolin Hfa | Albuterol Sulfate | 41 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 40 | 12 |
| Januvia | Sitagliptin Phosphate | 40 | suppressed |
| Alprazolam | Alprazolam | 39 | suppressed |
| Aripiprazole | Aripiprazole | 39 | 16 |
| Tizanidine Hcl | Tizanidine Hcl | 38 | 18 |
| Ropinirole Hcl | Ropinirole Hcl | 37 | 14 |
| Escitalopram Oxalate | Escitalopram Oxalate | 36 | 15 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 36 | 19 |
| Fluoxetine Hcl | Fluoxetine Hcl | 35 | 11 |
| Amitriptyline Hcl | Amitriptyline Hcl | 34 | suppressed |
| Vraylar | Cariprazine Hcl | 34 | suppressed |
| Allopurinol | Allopurinol | 33 | 12 |
| Clonazepam | Clonazepam | 33 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 33 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 33 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 32 | 12 |
| Ondansetron Hcl | Ondansetron Hcl | 32 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 31 | 29 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 31 | suppressed |
| Mirtazapine | Mirtazapine | 31 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 30 | suppressed |
| Lactulose | Lactulose | 30 | 14 |
| Methocarbamol | Methocarbamol | 30 | 12 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 29 | 13 |
| Oxybutynin Chloride | Oxybutynin Chloride | 29 | 11 |
| Bupropion Xl | Bupropion Hcl | 28 | 12 |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 27 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 27 | suppressed |
| Fluconazole | Fluconazole | 26 | 20 |
| Eszopiclone | Eszopiclone | 25 | suppressed |
| Prednisone | Prednisone | 25 | 23 |
| Propranolol Hcl | Propranolol Hcl | 25 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 25 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 25 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 24 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 24 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 24 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 23 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 23 | 19 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 22 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 22 | 20 |
| Fenofibrate | Fenofibrate,micronized | 22 | suppressed |
| Gemfibrozil | Gemfibrozil | 22 | suppressed |
| Pregabalin | Pregabalin | 22 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 22 | suppressed |
| Baclofen | Baclofen | 21 | suppressed |
| Finasteride | Finasteride | 21 | suppressed |
| Levemir Flexpen | Insulin Detemir | 21 | suppressed |
| Risperidone | Risperidone | 21 | suppressed |
| Topiramate | Topiramate | 21 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 20 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 20 | suppressed |
| Methylprednisolone | Methylprednisolone | 20 | 20 |
| Naproxen | Naproxen | 20 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 20 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 20 | suppressed |
| Linzess | Linaclotide | 19 | suppressed |
| Memantine Hcl | Memantine Hcl | 19 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 19 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 19 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 19 | suppressed |
| Tradjenta | Linagliptin | 19 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 18 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 18 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 18 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 18 | suppressed |
| Acyclovir | Acyclovir | 17 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 16 | suppressed |
| Fenofibrate | Fenofibrate | 16 | suppressed |
| Repatha Sureclick | Evolocumab | 16 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 15 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 15 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 15 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 15 | suppressed |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 14 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 14 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 14 | suppressed |
| Cephalexin | Cephalexin | 13 | suppressed |
| Glimepiride | Glimepiride | 13 | suppressed |
| Ubrelvy | Ubrogepant | 13 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 12 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 12 | suppressed |
| Klor-Con 10 | Potassium Chloride | 12 | suppressed |
| Xarelto | Rivaroxaban | 12 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 11 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 11 | suppressed |
| Estradiol | Estradiol | 11 | suppressed |
| Ibu | Ibuprofen | 11 | suppressed |
| Nystop | Nystatin | 11 | suppressed |
| Prolia | Denosumab | 11 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $92.83 · 5 records | ABBVIE INC. | AREXVY, Cologuard Collection Kit, Ozempic, QULIPTA, TRELEGY ELLIPTA | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error